160 related articles for article (PubMed ID: 30182439)
1. Celecoxib alleviates AKT/c-Met-triggered rapid hepatocarcinogenesis by suppressing a novel COX-2/AKT/FASN cascade.
Qiu Z; Zhang C; Zhou J; Hu J; Sheng L; Li X; Chen L; Li X; Deng X; Zheng G
Mol Carcinog; 2019 Jan; 58(1):31-41. PubMed ID: 30182439
[TBL] [Abstract][Full Text] [Related]
2. Osthole delays hepatocarcinogenesis in mice by suppressing AKT/FASN axis and ERK phosphorylation.
Mo Y; Wu Y; Li X; Rao H; Tian X; Wu D; Qiu Z; Zheng G; Hu J
Eur J Pharmacol; 2020 Jan; 867():172788. PubMed ID: 31712058
[TBL] [Abstract][Full Text] [Related]
3. Metformin delays AKT/c-Met-driven hepatocarcinogenesis by regulating signaling pathways for de novo lipogenesis and ATP generation.
Zhang C; Hu J; Sheng L; Yuan M; Wu Y; Chen L; Zheng G; Qiu Z
Toxicol Appl Pharmacol; 2019 Feb; 365():51-60. PubMed ID: 30625338
[TBL] [Abstract][Full Text] [Related]
4. Orlistat delays hepatocarcinogenesis in mice with hepatic co-activation of AKT and c-Met.
Zhang C; Sheng L; Yuan M; Hu J; Meng Y; Wu Y; Chen L; Yu H; Li S; Zheng G; Qiu Z
Toxicol Appl Pharmacol; 2020 Apr; 392():114918. PubMed ID: 32045588
[TBL] [Abstract][Full Text] [Related]
5. Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice.
Hu J; Che L; Li L; Pilo MG; Cigliano A; Ribback S; Li X; Latte G; Mela M; Evert M; Dombrowski F; Zheng G; Chen X; Calvisi DF
Sci Rep; 2016 Feb; 6():20484. PubMed ID: 26857837
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy of FASN inhibition in preclinical models of HCC.
Wang H; Zhou Y; Xu H; Wang X; Zhang Y; Shang R; O'Farrell M; Roessler S; Sticht C; Stahl A; Evert M; Calvisi DF; Zeng Y; Chen X
Hepatology; 2022 Oct; 76(4):951-966. PubMed ID: 35076948
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans.
Li L; Pilo GM; Li X; Cigliano A; Latte G; Che L; Joseph C; Mela M; Wang C; Jiang L; Ribback S; Simile MM; Pascale RM; Dombrowski F; Evert M; Semenkovich CF; Chen X; Calvisi DF
J Hepatol; 2016 Feb; 64(2):333-341. PubMed ID: 26476289
[TBL] [Abstract][Full Text] [Related]
8. Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib.
Xie H; Gao L; Chai N; Song J; Wang J; Song Z; Chen C; Pan Y; Zhao L; Sun S; Wu K; Feitelson MA; Liu J; Fan D
Mol Carcinog; 2009 Jan; 48(1):56-65. PubMed ID: 18506760
[TBL] [Abstract][Full Text] [Related]
9. Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans.
Che L; Chi W; Qiao Y; Zhang J; Song X; Liu Y; Li L; Jia J; Pilo MG; Wang J; Cigliano A; Ma Z; Kuang W; Tang Z; Zhang Z; Shui G; Ribback S; Dombrowski F; Evert M; Pascale RM; Cossu C; Pes GM; Osborne TF; Calvisi DF; Chen X; Chen L
Gut; 2020 Jan; 69(1):177-186. PubMed ID: 30954949
[TBL] [Abstract][Full Text] [Related]
10. Ellagic acid ameliorates AKT-driven hepatic steatosis in mice by suppressing de novo lipogenesis via the AKT/SREBP-1/FASN pathway.
Zhang C; Hu J; Sheng L; Yuan M; Wu Y; Chen L; Wang G; Qiu Z
Food Funct; 2019 Jun; 10(6):3410-3420. PubMed ID: 31123744
[TBL] [Abstract][Full Text] [Related]
11. Celecoxib Inhibits Hepatocellular Carcinoma Cell Growth and Migration by Targeting PNO1.
Dai H; Zhang S; Ma R; Pan L
Med Sci Monit; 2019 Sep; 25():7351-7360. PubMed ID: 31568401
[TBL] [Abstract][Full Text] [Related]
12. Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma.
Che L; Pilo MG; Cigliano A; Latte G; Simile MM; Ribback S; Dombrowski F; Evert M; Chen X; Calvisi DF
Cell Cycle; 2017 Mar; 16(6):499-507. PubMed ID: 28118080
[TBL] [Abstract][Full Text] [Related]
13. The chemokine receptor CCR10 promotes inflammation-driven hepatocarcinogenesis via PI3K/Akt pathway activation.
Wu Q; Chen JX; Chen Y; Cai LL; Wang XZ; Guo WH; Zheng JF
Cell Death Dis; 2018 Feb; 9(2):232. PubMed ID: 29445190
[TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis.
Leng J; Han C; Demetris AJ; Michalopoulos GK; Wu T
Hepatology; 2003 Sep; 38(3):756-68. PubMed ID: 12939602
[TBL] [Abstract][Full Text] [Related]
15. Celastrol-Loaded Galactosylated Liposomes Effectively Inhibit AKT/c-Met-Triggered Rapid Hepatocarcinogenesis in Mice.
Chen X; Hu X; Hu J; Qiu Z; Yuan M; Zheng G
Mol Pharm; 2020 Mar; 17(3):738-747. PubMed ID: 31904241
[TBL] [Abstract][Full Text] [Related]
16. The cyclooxygenase-2 inhibitor celecoxib attenuates hepatocellular carcinoma growth and c-Met expression in an orthotopic mouse model.
Yin J; Liu B; Li B; Liu Z; Xie X; Lv Z; Gao S; Guang J
Oncol Res; 2011; 19(3-4):131-9. PubMed ID: 21473289
[TBL] [Abstract][Full Text] [Related]
17. Pivotal Role of Fatty Acid Synthase in c-MYC Driven Hepatocarcinogenesis.
Jia J; Che L; Cigliano A; Wang X; Peitta G; Tao J; Zhong S; Ribback S; Evert M; Chen X; Calvisi DF
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33187130
[TBL] [Abstract][Full Text] [Related]
18. Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN.
Chu TH; Chan HH; Kuo HM; Liu LF; Hu TH; Sun CK; Kung ML; Lin SW; Wang EM; Ma YL; Cheng KH; Lai KH; Wen ZH; Hsu PI; Tai MH
Oncotarget; 2014 Mar; 5(6):1475-90. PubMed ID: 24721996
[TBL] [Abstract][Full Text] [Related]
19. Celecoxib attenuates hepatosteatosis by impairing de novo lipogenesis via Akt-dependent lipogenic pathway.
Zhang C; Lu Y; Song Y; Chen L; Hu J; Meng Y; Chen X; Li S; Zheng G; Qiu Z
J Cell Mol Med; 2022 Jul; 26(14):3995-4006. PubMed ID: 35713152
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of cyclooxygenase-2 in human HepG2, Bel-7402 and SMMC-7721 hepatoma cell lines and mechanism of cyclooxygenase-2 selective inhibitor celecoxib-induced cell growth inhibition and apoptosis.
Liu NB; Peng T; Pan C; Yao YY; Shen B; Leng J
World J Gastroenterol; 2005 Oct; 11(40):6281-7. PubMed ID: 16419156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]